Friday, 16 October 2026European Markets

SCATEC Stock Went Up By Over 16% In The Last 5 Sessions

Loading stream...

(VIANEWS) - Shares of SCATEC (Oslo Børs Benchmark Index_GI: SCATC.OL) rose by a staggering 16.75% in 5 sessions from kr62.7 to kr73.20 at 09:46 EST on Wednesday, after four consecutive sessions in a row of gains. Oslo Børs Benchmark Index_GI is falling 0.59% to kr1,201.41, after five consecutive sessions in a row of gains.

SCATEC's last close was kr70.60, 50.73% below its 52-week high of kr143.30.

About SCATEC

Scatec ASA, together with its subsidiaries, provides renewable energy solutions worldwide. The company operates through Power Production; Services; and Development & Construction segments. It develops, builds, owns, and operates solar, wind, and hydro power plants and storage solutions. The company is also involved in the engineering, procurement, construction, operation, maintenance, and asset management of power plants. It has a total of 4.6 GW in operation and under construction. The company was formerly known as Scatec Solar ASA and changed its name to Scatec ASA in November 2020. Scatec ASA was incorporated in 2007 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, SCATEC has a trailing twelve months EPS of kr-4.82.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -13.12%.

More news about SCATEC (SCATC.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com